GLPwatch
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582 · Unknown status
Last updated 2026-05-28This clinical trial is testing how a medication called GLP-1 affects blood sugar hormone levels after meals in adults with type 1 diabetes.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Phase2, Phase3
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 10 people Planned (estimated).
Who can join Ages 18+ · all sexes
Timeline Started 2015-07
What this study is testing ClinicalTrials.gov NCT02584582 ↗
Description as written by the study sponsor.
Aim: To investigate the glucagonostatic effect of glucagon-like peptide-1 (GLP-1) independent of the gastric emptying rate.
Treatments tested
- Liraglutide Drug
- Exenatide Drug
- Liquid meal test Procedure
- No drug (Baseline day) Other
| Main thing measured | Glucagon concentration (postprandial) |
|---|---|
| Sponsor | Hvidovre University Hospital |
| Conditions studied | Type 1 Diabetes |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02584582 ↗